Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.45 |
| ▸ | HTR2C | P28335 | 16/20 | 0.45 |
| ▸ | DRD2 | P14416 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | DRD5 | P21918 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761148 | 0.73 | ALDH1A1 (0.43) | HTR2ADRD2DRD3HTR1ADRD4 | |
| SCHEMBL2761116 | 0.70 | DRD4 (0.46) | KCNH2DRD3DRD4 | |
| SCHEMBL7261026 | 0.70 | SMO (0.41) | DRD2DRD3DRD4 | |
| SCHEMBL2760972 | 0.70 | HTR2A (0.41) | HTR2AHTR2CDRD2KCNH2HTR1A | |
| SCHEMBL5737789 | 0.69 | SMO (0.44) | DRD2DRD3HTR7DRD4 | |
| SCHEMBL5229642 | 0.69 | DRD2 (0.42) | HTR2AHTR2CDRD2KCNH2DRD3 | |
| SCHEMBL5907286 | 0.68 | CYP2A13 (0.44) | KCNH2 | |
| SCHEMBL2761085 | 0.68 | DHODH (0.43) | DRD2DRD3DRD4 | |
| SCHEMBL7262216 | 0.67 | HTR2C (0.40) | HTR2CDRD2DRD3DRD4 | |
| SCHEMBL7256544 | 0.67 | DRD4 (0.44) | DRD2DRD3HTR7DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842695-B2 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2010-11-30 | — | — | US | disclosed |
| EP-1611122-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010531-A1 | Substituted pyrazole compounds | HTR3A, HTR1A, HTR1D | HTR2A 18/4885HTR2C 9/4885DRD2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.